Virtual Reality as an Intervention for Chronic Pain in Multiple Sclerosis

Objective: To assess the feasibility and efficacy of virtual reality (VR) as an intervention for chronic pain due to MS. Background: VR technology is emerging as a platform for clinical interventions. VR uses a head mounted display that enables users to be immersed in controlled 360° virtual environments. The psychological immersion of the VR environment has been found to be effective in relieving acute pain. Here, we evaluated whether repeated immersive VR sessions could reduce the MS symptom of chronic pain. Design/Methods: The intervention consisted of 8 x 35-minute immersive VR sessions over the course of four weeks. Acute change in pain was measured before and after each VR session using a visual analog (VAS). Response to the intervention was measured with change in PROMIS pain scales administered at baseline and intervention end. Results: Participants were n=8 MS patients (n=7 RRMS, n=1 SPMS; 88% female; Mean 50.00 ±11.02 years, EDSS Conclusions: Repeated sessions of immersive VR experiences are tolerable and feasible for individuals with MS, and may provide a non-pharmacological tool for chronic pain management. Disclosure: Martin Malik has nothing to disclose. Mr. Shaw has nothing to disclose. Ms. Palmeri has nothing to disclose. Dr. Charvet has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Johnson \u0026 Johnson. An immediate family member of Dr. Charvet has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Springer Healthcare. The institution of Dr. Charvet has received research support from Biogen Idec.